Bharat Biotech to Produce 700 Million Doses of COVID-19 Vaccine Covaxin Annually

PBNS India
·2-min read

Bharat Biotech has announced that its production capacity will be increased to 700 million Covaxin doses annually. Manufacturing scale-up has been accomplished in stages in a stepwise manner at various facilities in Hyderabad and Bangalore.

Also Read | PBKS 60/4 in 11 Overs | PBKS vs SRH Live Score Updates of VIVO IPL 2021: Chris Gayle Dismissed on 15 By Rashid Khan

Capacity expansion in vaccine manufacturing is a long and tedious process, requiring investments of several millions of rupees and several years.
According to a statement from Bharat Biotech, the company is able to expand Covaxin manufacturing capability in a short time due to the availability of three new specially built facilities, the first of their kind for manufacturing in India.

The Government of India has approved a payment of about 4,500 crore rupees as advance to vaccine makers for ramping up their supplies including Bharat Biotech and Serum Institute of India (SII) that is producing AstraZeneca’s Covishield in India. Bharat Biotech Scales Up COVID-19 Vaccine Covaxin Production to 700 Million Doses Annually.

Also Read | How To Watch PBKS vs SRH IPL 2021 Live Streaming Online in India? Get Free Live Punjab Kings vs Sunrisers Hyderabad VIVO Indian Premier League 14 Cricket Match Score Updates on TV

Manufacturing collaborations are being discussed with partners in other countries who have prior experience in manufacturing inactivated viral vaccines on a commercial scale under biosafety containment.

Indian Immunologicals Tie-Up

Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for Covaxin in order to expand capacity. IIL has the skills and experience to produce inactivated viral vaccines at a commercial scale and under biosafety containment, and the technology transfer process is well underway.

‘’The protocols for manufacturing, testing, and release of inactivated vaccines have been tried, tested, and validated across several of our vaccines, these also meet the requirements of WHO, Indian, and other regulatory authorities. These protocols have delivered consistent results over a 15-year period with more than 300 million doses supplied globally, with excellent safety and performance record,’’ the statement said. COVID-19 Vaccine Update: Govt to Provide Rs 4,500 Crore Booster to Vaccine Manufacturers for Ramping Up Capacity.

About Covaxin

COVAXIN is India's indigenous COVID-19 vaccine. It was developed in partnership with the Indian Council of Medical Research (ICMR) and the National Institute of Virology by Bharat Biotech, a vaccine manufacturer based in Hyderabad (NIV).

Bharat Biotech’s Covaxin has also received Emergency Use Authorisation (EUA) in several countries so far, while several more applications are in process.